HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Exclusion Criteria

• •Patients who met any of the following criteria are excluded from the study:
• •1. Lymphoma patients with central nervous system (CNS) or leptomeningeal invasion
• •2. Inadequate organ function of liver and kidney
• •3. Carcinoma in situ of the breast History of liver disease, including cirrhosis, alcoholism, or currently known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
• •4. Any anti-tumor therapy including chemotherapy and radiotherapy within 3 weeks prior to the first dose of study drug
• •5. Within 7 days or approximately 5 half-lives (whichever is longer) prior to the first dose of the investigational drug, received any corticosteroids or approved small molecule targeted anti-cancer therapies.
• •6. Any monoclonal antibody used for anti-tumor therapy within 4 weeks or 2 half-lives prior to the first dose of study drug, whichever is longer
• •7. Prior use of any anti-tumor vaccine
• •8. Prior administration of radioimmunotherapy within 3 months prior to the first dose of study drug
• •9. Any uncontrolled active infection
• •10. History of drug-induced interstitial pneumonia